TABLE 1 

Demographic and clinical characteristics of 29 patients with early Lyme disease and 13 matched controlsa

VariableLyme disease patientseControlsfP valueg
Avg age (yr)52 (36–61) [20–71]50 (42–61) [22–70]0.62
Females10/29 (34.5)8/13 (61.5)0.22
Non-Hispanic Caucasians27/29 (93.1)12/13 (92.3)0.67
≥1 comorbidities11/29 (38.9)6/13 (46.2)0.62
    Carpal tunnel syndrome, mo2/29 (6.9)1/13 (7.7)0.41
    Diabetes, mo0/29 (0.0)2/13 (14.8)
    Heart disease, mo4/29 (13.8)1/13 (7.7)
    Lung disease, mo1/29 (3.4)0/13 (0.0)
    Migraines, mo4/29 (13.8)3/13 (23.1)
    Thyroid disease, mo3/29 (10.3)1/13 (7.7)
Two-tier serologybNAh
    Pretreatment positive14/28 (50.0)0/13 (0.0)
    Seroconverted during treatment6/28 (21.4)0/13 (0.0)
    Negative8/28 (28.6)13/13 (100)
Recovery status at V5NA
    Resolved15/28 (53.6)NA
    Persistent symptoms13/28 (46.4)NA
        Non-PTLDSc9/28 (32.1)NA
        PTLDSd4/28 (14.3)NA
        Lost to follow-up1/29 (2.8)NA
Sampling season
    V1<0.00001
        Spring3/29 (10.3)3/13 (23.1)
        Summer24/29 (82.8)1/13 (7.7)
        Autumn2/29 (6.9)1/13 (7.7)
        Winter0/29 (0.0)8/13 (61.5)
    V2<0.00001
        Spring1/28 (3.6)3/13 (23.1)
        Summer22/28 (78.6)1/13 (7.7)
        Autumn5/28 (17.9)1/13 (7.7)
        Winter0/28 (0.0)8/13 (61.5)
    V50.023
        Spring7/28 (25.0)3/13 (23.1)
        Summer0/28 (0.0)1/13 (7.7)
        Autumn1/28 (3.6)1/13 (7.7)
        Winter20/28 (71.4)8/13 (61.5)
  • a Number/total (%) reported for categorical variables and median, IQR interquartile range (in parentheses), and range (in brackets) presented for continuous variables.

  • b One patient missing two-tier serology data.

  • c Non-PTLDS (persistent symptoms with no functional decline).

  • d PTLDS (persistent symptoms with functional decline).

  • e n = 29.

  • f n = 13.

  • g Lyme disease patients versus controls.

  • h NA, not applicable.